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Total lifetime exposure to estrogen (E2) is the 
single greatest environmental risk factor for 
breast cancer (Dunn et al. 2005). The clas-
sic pathway of E2-mediated carcino  genesis is 
through the estrogen receptor (ER), where E2 
alters gene expression to increase cell prolifera-
tion (Currier et al. 2005). Consequently, it 
has been hypothesized that E2 metabolism 
acts to decrease breast cancer risk (Holcomb 
and Safe 1994). Yet, some E2 metabo-
lites may increase breast cancer risk through 
DNA damage (Cavalieri and Rogan 2004; 
Cavalieri et al. 1997). E2 is metabolized by 
cytochrome P450 (CYP) 1B1 into reactive 
catechols that under  go redox cycling, resulting 
in oxidative stress, DNA adduct formation, 
and DNA mutations (Cavalieri and Rogan 
2004; Chakravarti et al. 2001; Mitrunen and 
Hirvonen 2003). The phase II enzyme cat-
echol-  O-  methyltransferase (COMT) miti-
gates this genotoxicity by inactivating the E2 
catechols via O-methylation. 2,3,7,8-Tet-
rachlorodibenzo-p-dioxin (TCDD) and 
other aryl hydrocarbon receptor (AhR) 
agonists can modulate E2 activity through 
induction of E2-metabolizing CYP1A1 and 
CYP1B1 enzymes (Mitrunen and Hirvonen 
2003). Thus, TCDD has the potential to 
modify breast cancer risk through alteration of 
ER-mediated proliferation or CYP1-mediated 
DNA damage (Mitrunen and Hirvonen 
2003). The influence of TCDD exposure dur-
ing early-life periods may be more pronounced 
because early-life estrogenic exposures appear 
to contribute to a greater risk of breast cancer 
than do exposures later in life (Dolinoy et al. 
2007; Hilakivi-Clarke et al. 1999, 2000).
An industrial accident in Seveso, Italy, 
supports the link between early-life TCDD 
exposure and cancer risk. TCDD exposure 
was positively associated with breast cancer 
risk only in women who were infants up to 
40 years of age at the time of the accident 
(Warner et al. 2002). Early-life TCDD expo-
sure, particularly peri  natally, has also been 
associated with increased mammary tumori-
genesis in several rodent models (Brown et al. 
1998; Desaulniers et al. 2001). Paradoxically, 
although greater E2 exposure in adolescents 
with early menses contributes to increased 
breast cancer risk (Vihko and Apter 1984), 
delayed pubertal breast differentiation may 
also increase breast cancer risk. Rodent models 
have shown that peri  natal TCDD exposure 
increases mammary tumor risk through altered 
mammary differentiation (Brown et al. 1998; 
Fenton et al. 2002), which extends the period 
in which the rapidly proliferating pro  genitor 
cells of the terminal end buds (TEBs) are 
susceptible to carcinogenic insult (Birnbaum 
and Fenton 2003). A similar developmental 
delay has been reported in humans; as serum 
TCDD concentrations increase in either pre-
natal or pre  menarcheal samples, the timing 
of pubertal breast development is delayed 
(Den Hond et al. 2002; Leijs et al. 2008).
Like TCDD and E2 exposures, obesity 
may have age-specific or developmental-
stage–specific effects on breast cancer risk 
(De Assis and Hilakivi-Clarke 2006). Obesity 
may also modify breast cancer risk through 
increased persistence of lipophilic TCDD in 
adipose tissue, including mammary stroma 
(Emond et al. 2006). Consequently, mam-
mary glands of obese individuals are likely 
exposed to greater TCDD levels than in their 
lean counterparts (Emond et al. 2006; Harrad 
et al. 2003; Hooper et al. 1998; Michalek 
and Tripathi 1999). Because obese individ-
uals retain more TCDD, maternal TCDD 
exposure may result in altered susceptibility 
to breast cancer among their offspring. In 
the present study we used the 7,12-dimethyl-
benz[a]anthracene (DMBA) mouse model of 
breast cancer to examine the mechanistic basis 
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Ba c k g r o u n d: Results from previous studies have suggested that breast cancer risk correlates with 
total lifetime exposure to estrogens and that early-life 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) 
exposure or diets high in fat can also increase cancer risk.
oBjectives: Because both TCDD and diet affect the estrogen pathway, we examined how TCDD 
and a high-fat diet (HFD) interact to alter breast cancer susceptibility.
Me t h o d s : We exposed pregnant female FVB/NJ mice (12.5 days post  coitus) to 1 µg/kg TCDD or 
vehicle; at parturition, the dams were randomly assigned to a low-fat diet (LFD) or a high-fat diet 
(HFD). Female offspring were maintained on the same diets after weaning and were exposed to 7,12-
dimethylbenz[a]anthracene on post  natal days (PNDs) 35, 49, and 63 to initiate mammary tumors. 
A second cohort of females was treated identically until PND35 or PND49, when mammary gland 
morphology was examined, or PND50, when mammary gland mRNA was analyzed. 
re s u l t s: We found that maternal TCDD exposure doubled mammary tumor incidence only in mice 
fed the HFD. Among HFD-fed mice, maternal TCDD exposure caused rapid mammary develop-
ment with increased Cyp1b1 (cytochrome P450 1B1) expression and decreased Comt (catechol- 
O-methyltransferase) expression in mammary tissue. Maternal TCDD exposure also increased 
mammary tumor Cyp1b1 expression. 
co n c l u s i o n s: Our data suggest that the HFD increases sensitivity to maternal TCDD exposure, 
resulting in increased breast cancer incidence, by changing metabolism capability. These results pro-
vide a mechanism to explain epidemiological data linking early-life TCDD exposure and diets high 
in fat to increased risk for breast cancer in humans.
key w o r d s : COMT, CYP1B1, dioxin, high-fat diet, mammary cancer, puberty. Environ Health 
Perspect 118:596–601 (2010).  doi:10.1289/ehp.0901047 [Online 9 December 2009]Dioxin and high-fat diet increase mammary cancer
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of how maternal TCDD exposure and obesity-
associated high-fat diets (HFDs) increase can-
cer risk. We found that the combined effect 
of maternal TCDD exposure and an HFD 
increases mammary cancer risk through altera-
tions in metabolism capability and the rate of 
breast development.
Materials and Methods
Mice and experimental design. We used a 
randomized 2 × 2 factorial design with the 
TCDD-responsive mouse strain FVB/NJ 
(Jackson Laboratory, Bar Harbor, ME). At 
12.5 days post  coitus, nulliparous dams were 
administered 1 µg/kg TCDD orally (n = 13 
dams; 1.8–1.9 µL TCDD solution/g mouse; 
99.9% purity; Ultra Scientific, North 
Kingstown, RI) or an equivalent volume of 
vehicle (n = 14 dams; 95%/5% olive oil/tolu-
ene by volume; 99.9% purity; Sigma-Aldrich, 
St. Louis, MO). Litters were assigned to 
the HFD (n = 13 litters; D12451; Research 
Diets, New Brunswick, NJ) or control low-
fat diet (LFD; n = 14 litters; D12450B; 
Research Diets) from post  natal day (PND) 0 
(parturition) until euthanasia. The HFD was 
4.73 kcal/g (20% protein, 35% carbohydrate, 
and 45% fat by total kcal), and the LFD was 
3.85 kcal/g (20% protein, 70% carbohydrate, 
and 10% fat by total kcal). The primary differ-
ences between the matched diets are decreased 
cornstarch and sucrose and increased malto-
dextrin and lard in the HFD (291, 691, 400, 
and 1,598 kcal, respectively) compared with 
the LFD (1,260, 1,400, 140, and 180 kcal, 
respectively). Mice raised on the HFD were 
significantly heavier than those raised on the 
LFD beginning at pre    weaning (La Merrill 
et al. 2009a). Further, body weight, percent 
body fat, and fasting blood glucose of mice fed 
the HFD significantly increased with age rela-
tive to mice fed the LFD. However maternal 
TCDD exposure did not alter body weight, 
percent body fat, or fasting blood glucose 
(La Merrill et al. 2009a).
On PND4, all litters were culled to four 
pups, maximizing the number of female pups 
per litter. On PND21, all dams and any male 
offspring were removed from the cages. On 
PNDs 35, 49, and 63, all the female mice 
were administered 60 mg/kg DMBA orally 
(2.4 µL DMBA solution/g mouse; 95%/5% 
olive oil/toluene by volume; 98% purity; 
Sigma-Aldrich), hereafter referred to as the 
mammary cancer cohort. DMBA-treated mice 
were palpated for mammary tumors biweekly 
beginning on PND83. 
In the parallel mammary gland cohort, 
mice were treated identically through PND49, 
inclusive of DMBA dosing, to examine poten-
tially differential mammary gland morphology 
present when DMBA was administered in the 
mammary cancer cohort (PND35, PND49). 
mRNA expression was evaluated when 
mammary gland morphology was equivocal 
across exposure groups (PND50).
All mice were given water ad libitum in 
sterile ventilated cages in a facility approved by 
the American Association for the Accreditation 
of Laboratory Animal Care. Euthanasia was 
performed by CO2 asphyxiation on PNDs 35, 
49, or 50, or when tumors were ≥ 1 cm in 
diameter or mice reached 11 months of age, 
whichever came first. All mice were treated 
humanely and with regard for alleviation of 
suffering, and all studies were approved by the 
University of North Carolina–Chapel Hill 
Institutional Animal Care and Use Committee.
Histological analyses. Mammary tumors 
from the mammary cancer cohort mice were 
bisected at necropsy. One-half was flash-frozen, 
and the other half was fixed overnight at 4°C 
in 4% para  formaldehyde before dehydrating, 
embedding in paraffin, and sectioning. We 
evaluated tissue sections (4 µm; stained with 
hematoxylin and eosin) for pathology. 
To determine tumor expression of ERBB2   
(v-erb-b2 erythroblastic leukemia viral oncogene 
homolog 2) in mammary cancer cohort mice, 
paraffin sections were placed onto Superfrost/
Plus slides (Fisher Scientific, Pittsburgh, PA), 
and then deparaffinized and cleared. After inhi-
bition of endogenous peroxidase activity in a 
solution of 3% hydrogen peroxide in methanol, 
sections were hydrated in graded alcohols to 
distilled water. Antigen retrieval was performed 
using high-temperature/high-pressure incuba-
tion in 0.01 mol/L citric acid buffer (pH 6.0) 
for 12 min. Slides were allowed to cool for 
30 min in citric acid buffer and then trans-
ferred to phosphate-buffered saline (PBS) at 
pH 7.4. Universal blocking reagent (BioGenex, 
San Ramon, CA) was applied to sections and 
incubated for 30 min in a humidified cham-
ber at room temperature. ERBB2 anti  body 
(Neomarkers, Fremont, CA) and rabbit second-
ary anti  body (Santa Cruz Biotechnology, Santa 
Cruz, CA) diluted in PBS without ovalbumin 
were incubated for 1 hr each, and then sections 
were rinsed in PBS.
On PND35 and PND49, inguinal mam-
mary glands from mammary gland cohort mice 
were weighed, fixed, and stained with carmine 
alum to evaluate fat pad length, number of 
TEBs, and branch elongation according to 
published methods (Fenton et al. 2002).
Gene expression. For RNA extraction, we 
flash-froze and pulverized the other half of 
each mammary tumor and a grossly normal 
gland—defined as a gland from which no 
palpable or visible (5× dissecting scope) foci 
were observed—from the same mouse in the 
mammary cancer cohort study. PND50 mam-
mary glands from mice in the mammary gland 
cohort study were flash frozen, pulverized, 
and pooled within litter for RNA extraction 
(TRIzol Reagent, Invitrogen). We used the 
High-Capacity cDNA Archive Kit (Applied 
Biosystems Inc., Foster City, CA) to generate 
cDNA for polymerase chain reaction (PCR) 
analysis. 
Real-time PCR was performed on 100 µg 
total RNA to assess relative transcript levels 
of Cyp1a1, Cyp1b1, Insig1 (insulin induced 
gene 1), Ccdn1 (cyclin D1), Myc (myelo  cyto-
matosis oncogene), Egf (epidermal growth 
factor), Ereg (epiregulin), Esr1 (estrogen recep-
tor 1), and Esr2 (estrogen receptor 2) using 
Assays-on-Demand (Applied Biosystems) with 
Gusb (glucuronidase, beta) as the endogenous 
control and K18 (keratin 18) as an epithelial-
specific marker in PND50 mammary glands 
(Livak and Schmittgen 2001). Real-time PCR 
was also performed on Cyp1b1 and Comt to 
determine relative transcript levels using Tbp 
(TATA box binding protein) as the endoge-
nous control in mammary tumors and matched 
controls (Applied Biosystems). Mammary 
gland RNA collected from mammary gland 
cohort mice at PND50 and Mouse Universal 
Reference RNA (Stratagene, La Jolla, CA), was 
prepared for global gene expression analysis 
using the Low RNA Input Linear Amplification 
Kit (Agilent Technologies, Santa Clara CA). 
The resulting cRNA was labeled with either 
Cy3-CTP (Mouse Universal Reference RNA) 
or Cy5-CTP (PerkinElmer, Waltham, MA) 
and purified (RNeasy; Qiagen, Valencia, CA). 
We evaluated global gene expression using a 
4 × 44,000 micro  array (Agilent Technologies) 
(Syed and Threadgill 2006).
Statistics. We evaluated lesion latency 
[defined as time (PND) to reach palpable lesion] 
and lesion aggression [defined as the time from 
first palpable mass to time of mass ≥ 1 cm in 
diameter (PND)] by the hazard ratio (HR), 
using a mixed survival model in SUDAAN 9.0 
software (Research Triangle Institute, Research 
Triangle Park, NC), with litter as a random 
effect. Lesion incidence (defined as the pro-
portion of mice with mammary lesions per lit-
ter) was analyzed with Fisher’s exact test (SAS, 
version 9.1.3; SAS Institute Inc., Cary, NC). 
Significance of immuno  histo  chemistry flores-
cence was determined using the method of 
Rosner et al. (2002). We used analysis of vari-
ance to evaluate the fixed effects of HFD and 
maternal TCDD exposure and their inter  action 
on branch elongation, fat pad length, number 
of TEBs in PND35 and PND49 mammary 
glands, and Comt, Ccdn1, Cyp1a1, Cyp1a2, 
Cyp1b1, Insig1, Myc, Ereg, Ahr, Egfr (epidermal 
growth factor receptor), Esr1, and Esr2 levels in 
PND50 mammary glands (Proc GLM; SAS). 
The fixed effects of tissue status (with tumor or 
normal) and maternal TCDD, their interaction, 
and litter as a random effect were modeled for 
Comt and Cyp1b1 levels in mammary tumors 
and matched normal tissue (Proc GLM). 
Microarrays were scanned on an Agilent 
scanner and analyzed using default settings of 
Feature Extraction version 9.1 (Agilent). We La Merrill et al.
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uploaded microarray raw data into the UNC 
Microarray Database (http://genome.unc.edu) 
and performed Log2 R/G Lowess normal-
ization on the Cy3 and Cy5 channels. The 
lowess-normalized data was quantile normal-
ized (Barbacioru et al. 2006; Yang and Thorne 
2003). Differentially expressed genes were iden-
tified using false discovery rate (FDR) < 0.05 
threshold (SAM software, Stanford University, 
Stanford, CA) as described by Tusher et al. 
(2001). Significant genes and their fold change 
values generated in SAM were imported into 
Ingenuity Pathways Analysis (IPA 6.5–1602; 
Ingenuity Systems Inc., Redwood City, CA), 
where they were mapped to correspond-
ing gene objects in the Ingenuity Pathways 
Knowledge Base (IPKB). The curated IPKB 
generated functional analy  ses of differentially 
expressed genes using Fisher’s exact test to cal-
culate the probability (p-value) that each bio-
logical function and/or disease assigned to the 
gene set was due to chance alone.
Results
Increased incidence of mammary tumors. We 
found palpable lesions of both dermal and 
mammary origin after oral DMBA exposure, 
with 83% of mammary cancer cohort mice 
developing dermal lesions. Consistent with 
previous rat studies (Brown et al. 1998; 
Desaulniers et al. 2001), mammary cancer 
cohort mice fed LFD after maternal TCDD 
exposure had an average 59.7 days shorter 
latency to the first palpable lesions of either 
origin compared with those treated with vehi-
cle (HR = 2.01081, p < 0.05; Figure 1A), 
although no mammary tumors arose in mam-
mary cancer cohort LFD-fed mice exposed 
to TCDD (Figure 1B). The latency of the 
first palpable lesion of either origin was on 
average 80.5 days shorter for mammary can-
cer cohort mice fed HFD than for those fed 
LFD (HR = 0.0075, p < 0.01; Figure 1A), 
and these lesions grew faster (HR = 0.24827, 
p < 0.05; data not shown).
Because of the increased incidence of 
mammary tumors with either HFD or peri-
natal TCDD exposure seen in previous stud-
ies (Brown et al. 1998; Desaulniers et al. 
2001; Hilakivi-Clarke et al 1997), we antici-
pated that HFD-fed mammary cancer cohort 
mice might have heightened susceptibility to 
maternal TCDD exposure. Consistent with 
this expectation, we observed a significant 
increase in mammary lesions of mice fed HFD 
after maternal TCDD exposure (p < 0.0001; 
Figure 1B). Mammary cancer cohort mice fed 
HFD had twice as many mammary lesions 
as mice fed LFD. Although no mammary 
lesions arose in litters exposed to TCDD 
and LFD, and one-third of unexposed litters 
fed HFD had mammary lesions, every lit-
ter exposed to both TCDD and HFD devel-
oped mammary lesions. Mammary lesions 
were primarily adeno  squamous carcinomas, 
typical of the DMBA model (Figure 2A). 
However, several lesion types were clustered 
with respect to treatment. We found three 
adeno  myo  epitheliomas, a rare lesion in the 
DMBA model, exclusively in mammary can-
cer cohort mice peri  natally exposed to TCDD 
and fed HFD (Figure 2B). In mammary can-
cer cohort mice treated with vehicle and fed 
HFD, we found two solid nodular ERBB2-
positive tumors with zonation (Figure 2C) 
(Rosner et al. 2002).
Transient alteration of pubertal mammary 
gland morphology. Previous studies demon-
strated a correlation among perinatal TCDD 
exposure, altered pubertal mammary differ-
entiation, and increased mammary tumors in 
rats (Brown et al. 1998; Fenton et al. 2002). 
To determine whether alteration in mammary 
develop  ment could have contributed to dif-
ferential cancer susceptibility in mice, we meas-
ured the effect of diet and TCDD exposure 
on mammary development in the mammary 
gland cohort. The combined effects of maternal 
TCDD and HFD exposures on the number of 
TEBs at PND35 deviated significantly from 
an additive model (p < 0.001 for inter  action; 
Figure 3A); treatment with either TCDD or 
HFD increased the number of TEBs com-
pared with mice treated with LFD and vehicle, 
whereas treatment with TCDD and HFD 
jointly decreased the number of TEBs. Among 
mammary gland cohort mice fed LFD, there 
was an average of 22 more TEBs per mouse 
with maternal TCDD exposure compared 
with vehicle. However, mammary gland cohort 
mice fed HFD had on average 18 fewer TEBs 
per mouse with maternal TCDD exposure 
Figure 1. Effect of maternal TCDD and diet on palpable tumor latency and mammary tumor incidence in 
mammary cancer cohort mice treated with DMBA on PNDs 35, 49, and 63. (A) Time (PND) until first pal-
pable tumor was detected (n = 28 litters). Tumor latency of HFD-fed mice treated with vehicle did not differ 
from that of HFD-fed mice treated with TCDD. Mean ± SD life spans were 255.1± 76.8 for LFD plus vehicle; 
213.4 ± 83.8 for LFD plus TCDD; 167.2 ± 48.1 for HFD plus vehicle; and 178.8 ± 64.0 for HFD plusTCDD. 
(B) Percentage of mice with mammary tumors (n = 28 litters). 
*p < 0.0001 compared with HFD-fed mice treated with vehicle.
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(p < 0.01), a level comparable to that of the 
LFD group without TCDD treatment. We 
found no significant difference in the number 
of TEBs between HFD/vehicle mice compared 
with LFD/TCDD mice, or between HFD/
TCDD mice compared with LFD/vehicle mice 
(Figure 3A). 
Although the mean number of TEBs 
(Figure 3A), branch elongation (Figure 3B), 
and fat pad length (Figure 3C) were greater 
among mammary gland cohort mice fed HFD 
relative to LFD (26.3 vs. 18.6, 1.21 mm vs. 
0.70 mm, and 1.64 mm vs. 1.39 mm, respec-
tively), only branch elongation was significantly 
increased in the HFD group relative to the 
LFD group at PND35 (p < 0.05; Figure 3B).
Although perinatal TCDD exposure in rats 
prevents full differentiation of pubertal mam-
mary glands (Fenton et al. 2002), we found 
the effects to be transient. By PND49, neither 
HFD nor maternal TCDD exposure affected 
the number of TEBs (data not shown). At 
PND49, fat pad length and ductal elongation 
were also unchanged by HFD and maternal 
TCDD exposure, and at PND50, we found 
no treatment-associated changes in expression 
of mammary morphology regulators Egf and 
Ereg (data not shown). These data indicate that 
mammary glands from mice exposed to both 
TCDD and HFD had a more rapid rate of 
maturation after PND35 than those from mice 
with only one treatment.
Altered expression of genes involved with 
metabolism. Because mammary carcinogenesis 
may involve either E2- or ER-mediated pro-
liferation or E2-metabolite–mediated genetic 
instability (Bolton and Thatcher 2008; Yager 
and Davidson 2006), we surveyed the tran-
scriptome of mammary gland cohort mice for 
indications of these mechanisms. Analysis of 
the effect of diet on global gene expression 
demonstrated a subtle role for pubertal onset 
of obesity in modifying metabolism of carbo-
hydrates, lipids, and proteins (p < 0.01), as 
reflected in the differential expression of 134 
genes [FDR < 0.05; see Supplemental Material, 
Table 1 (doi:10.1289/ehp.0901047)]. Cancer 
was the disease/disorder category most signifi-
cantly enriched (n = 20 differentially expressed 
transcripts; see Supplemental Material, 
Table 2) by mRNA due to HFD (p < 0.0001). 
However, most of these transcripts were down-
regulated by diet, whereas only Lrp1 (low den-
sity lipoprotein receptor-related protein 1) and 
Aldh1a1 (aldehyde dehydrogenase family 1, 
subfamily A1) were modestly up-regulated 
by HFD, 1.6- and 1.8-fold, respectively (see 
Supplemental Material, Table 1). Lrp1 was 
also the only gene among those associated with 
DNA damage that was significantly enriched 
by HFD (p < 0.01). Cellular proliferation 
(p < 0.01) was significantly enriched in the 
differential expression pattern caused by HFD. 
All genes associated with cell proliferation were 
down-regulated, suggesting that HFD may 
have reduced proliferation. No gene expression 
changes were significantly altered at the FDR 
< 0.05 level by maternal exposure to TCDD.
We used quantitative real-time PCR to fur-
ther examine the influence of TCDD and HFD 
on transcription associated with E2 metabolism 
and proliferation. We examined expression of 
Cyp1a1, Cyp1b1, and Comt as indicators of 
altered E2 metabolism capability in the mam-
mary gland cohort mice. Cyp1a1 expression 
was not altered by any treatment (Figure 4A). 
Exposure to HFD/TCDD increased epithelial 
Cyp1b1 mRNA expression (Figure 4B) and 
decreased Comt mRNA expression (Figure 4C) 
in mammary glands relative to HFD/vehicle, 
LFD/vehicle, or LFD/TCDD mice (p < 0.05), 
but TCDD had no effect on expression in 
mice fed LFD. Cyp1b1 was also increased in 
mammary tumors compared with matched 
normal mammary glands in the mammary 
cancer cohort (p < 0.05; Figure 4D). Among 
mammary tumors, Cyp1b1 was elevated sub-
stantially by maternal TCDD exposure relative 
to vehicle (p < 0.05; Figure 4D). As opposed 
to E2 metabolism indicators, we observed no 
treatment-associated changes for the expression 
of the E2/ER proliferation indicators Ccdn1, 
Myc, Egfr, Esr1, or Esr2 in mammary glands in 
the mammary gland cohort (data not shown). 
Together, these data support metabolism, and 
not E2/ER-mediated proliferation, as the likely 
mechanism under  lying increased incidence of 
cancer caused by a combination of TCDD and 
HFD exposures.
Discussion
Human and rat studies suggest that early-life 
TCDD exposure increases mammary cancer 
incidence (Brown et al. 1998; Desaulniers 
et al. 2001; Warner et al. 2002), which we 
Figure 3. Interaction of maternal TCDD exposure and diet on mammary gland morphology at PND 35 in the 
mammary gland cohort. (A) Number of TEBs. (B) Branch elongation. (C) Fat pad length. Values shown are 
mean ± SE; animals are from a total of 20 litters.
**p < 0.01.
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Figure 4. Effects of maternal TCDD and diet on E2 metabolism–associated gene expression. (A) Fold change in Cyp1a1 expression in mammary glands of the mam-
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confirmed in the present study in HFD-fed 
mice. There is substantial evidence that mater-
nal estrogenic exposures, such as TCDD, 
HFD, and obesity, increase E2-responsive 
cancer incidence in adult offspring (Brown 
et al. 1998; Ho et al. 2006; Li et al. 1997; 
Prins et al. 2008). However, the mechanism 
by which this occurs is unknown. In the pres-
ent study we investigated the mechanism by 
which HFD and maternal TCDD exposure 
increase breast cancer risk.
In the present study, DMBA-treated mice 
fed HFD had increased mammary tumor inci-
dence and shortened latency relative to those 
fed LFD. We have shown previously that LFD 
has significantly greater estrogenic activity than 
does HFD, eliminating a direct role of diet on 
HFD-associated mammary tumor phenotypes 
(La Merrill et al. 2009a). HFD significantly 
down-regulated many of the genes found to be 
up-regulated in a lipid metabolic gene network 
associated with human breast cancer (e.g. Acyl, 
Insig1, Elovl6, Fasn, Scd) (Pitroda et al. 2009). 
Yet the two HFD up-regulated transcripts 
identified as significantly associated with cancer 
by the IPKB are also involved in lipid metabo-
lism. Aldh1a1, which metabolizes products 
of lipid peroxidation (Alnouti and Klaassen 
2008), has been found to be up-regulated in 
human breast cancer samples (Wilson et al. 
2002). Similarly, Lrp1 is involved with breast 
cancer cell migration (Dedieu et al. 2008), 
DNA damage (Ling et al. 2007), and obe-
sity (Hofmann 2007). Thus, change in gene 
expression due to HFD is consistent with the 
genotoxicity hypothesis.
We have also shown that HFD increased 
adiposity and fasting blood glucose from 
puberty throughout life in these same mice 
(La Merrill et al. 2009a). Thus, the mammary 
cancer cohort mice fed HFD have greater adi-
posity and risk for metabolic syndrome than 
those fed LFD. Although increased adiposity 
slows TCDD elimination, extending its half-
life (Michalek and Tripathi 1999), pharmaco-
kinetic models designed to account for this 
predict that virtually no TCDD is stored in 
the mice at the time of tumor onset (Emond 
et al. 2006). Further, because Cyp1a1, highly 
inducible by TCDD, was not significantly 
induced by TCDD at PND50 in the mam-
mary gland cohort, it is likely that very little 
TCDD remained in the mice at that age.
Obesity increases post  menopausal breast 
cancer in women (Lorincz and Sukumar 
2006), which may occur because of heightened 
E2 production in mammary adipose tissue 
(Simpson 2003). Further, several studies have 
found that increased adiposity interacts with 
alleles of E2-metabolizing enzymes to increase 
breast cancer risk (Kocabas et al. 2002, 2005; 
Thompson et al. 1998). Thus the doubled 
mammary tumor incidence in HFD-fed mice 
exposed to maternal TCDD here may reflect 
higher steady-state levels of both E2 and its 
toxic metabolites.
TCDD up-regulated epithelial Cyp1b1 
expression and decreased Comt expression in 
pubertal mammary glands from mammary 
gland cohort mice fed HFD, indicating a role 
of the E2 metabolism genotoxicity pathway 
in cancer etiology (Figure 5), consistent with 
studies showing a role for maternal COMT 
and CYP1B1 in breast cancer risk of exposed 
daughters (Inoue et al. 1980; Sata et al. 2006). 
Although modest changes are common in 
constitutive Cyp1b1, environ  mental expo-
sures infrequently change Comt expression; 
one rat model of aryl hydro  carbon exposure 
showed decreased hepatic Comt expression 
(Desaulniers et al. 2005). Human studies have 
suggested that high-activity CYP1B1 alleles 
and low-activity COMT alleles are associated 
with increased risk of breast cancer (Wen et al. 
2007) and other E2-responsive cancers (Nock 
et al. 2006; Sellers et al. 2005; Zimarina et al. 
2004). Consequently, inter  actions between 
E2 exposures during key life stages as modeled 
here and the E2-regulating genes Cyp1b1 and 
Comt may modify breast cancer risk (Mitrunen 
et al. 2001).
Maternal TCDD also substantially 
increased Cyp1b1 expression in mammary 
tumors, suggesting that changes in mammary 
progenitor cells resulted in increased Cyp1b1 
that persisted through their expansion to 
tumors. However, TEB numbers were reduced 
in mice fed HFD and exposed to TCDD in the 
mammary gland cohort. Further, identically 
treated DBA/2J mice also have reduced TEB 
numbers at PND35 (La Merrill et al. 2009b). 
Because TEB number correlates with the carci-
nogenicity of DMBA (Russo and Russo 1978), 
we did not expect this TCDD delay of puber-
tal mammary growth. Our observations indi-
cate that altered mammary morphology during 
cancer initiation (PND35) is not the primary 
mechanism for elevated tumor incidence 
caused by maternal TCDD and HFD expo-
sure. However, mammary gland morphology 
was unchanged by diet and maternal TCDD 
at subsequent ages, suggesting rapid compensa-
tory growth in mammary glands exposed to 
HFD and maternal TCDD. This rapid com-
pensatory growth hypothesis is substantiated 
by the low Comt expression seen in these mice 
by Eriksson et al. (2005). Rapid compensatory 
mammary growth between the first and sec-
ond dose of DMBA could have contributed to 
increased tumor incidence in two ways. Rapid 
growth might narrow the window of time 
available for repair of DNA damage potentially 
caused by altered E2 metabolism (Budzowska 
and Kanaar 2009; Chakravarti et al. 2001). 
Second, rapid mammary growth would facili-
tate expansion of Cyp1b1-expressing mammary 
epithelial cell populations into tumor cells. 
Although no human studies document the 
influence of dioxin on the tempo of puberty, 
the dioxin-induced delay in pubertal mammary 
growth and later mammary tumor incidence 
seen here has been demonstrated in human 
studies (Den Hond et al. 2002; Leijs et al. 
2008; Warner et al. 2002).
Conclusion
Maintenance of mice on HFD increased the 
effects of maternal TCDD on mammary can-
cer risk in offspring through alterations in 
metabolism capability. E2-like exposures, such 
as an obeso  genic diet, combined with maternal 
TCDD exposure may increase the risk of breast 
cancer in the subsequent generation. The incon-
sistent relationships between CYP1B1, COMT, 
and breast cancer risk seen across epidemiol-
ogy studies may reflect divergent risk associ-
ated with variable environmental E2 exposures 
(Justenhoven et al. 2007; Le Marchand et al. 
2005; McGrath et al. 2004). This may under-
state the susceptibility to TCDD among over-
weight, genetically susceptible adolescents. Our 
results highlight the importance of using experi-
mental animal models to evaluate the unique 
susceptibilities of varying subpopulations to 
breast cancer risk and to ensure that risk assess-
ments in humans do not fail to take susceptible 
subpopulations into account.
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